Related Experiment Video
Updated: Sep 4, 2025
11:17
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
7.4K
Recent Advances with KDM4 Inhibitors and Potential Applications
Qiong Wu1, Brandon Young2, Yan Wang3
1Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Journal of Medicinal Chemistry
|July 15, 2022
Summary
Histone lysine demethylase 4 (KDM4) enzymes regulate key cellular processes. Inhibitors targeting KDM4 offer potential therapeutic strategies for cancers and other diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Epigenetics
Background:
- The histone lysine demethylase 4 (KDM4) family regulates gene transcription, DNA repair, and metabolism.
- KDM4 dysregulation is linked to human disorders like cancer, obesity, and cardiovascular diseases.
Purpose of the Study:
- To provide an overview of KDM4 inhibitors.
- To discuss the current status, challenges, and opportunities in developing KDM4-based anticancer therapeutics.
Main Methods:
- Literature review of KDM4 inhibitor research.
- Analysis of KDM4's role in disease pathogenesis.
Main Results:
- KDM4 inhibitors are valuable tools for understanding KDM4 functions in disease.
- Selective KDM4 inhibitors present therapeutic potential for various disorders.
Conclusions:
- KDM4 inhibitors are crucial for both research and therapeutic development.
- Further research into KDM4 inhibitors could yield novel anticancer treatments.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
246
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
246
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
56
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
56
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K